Delivery Order SPE2DB22D2206-SPE2DB25FJC61
- Not listed
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,623.60 contract is for the delivery of the prescription medication Samsca 15 mg tablets, with a performance period ending on May 14, 2025. AmerisourceBergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $44,080.92 firm fixed price delivery order is for the supply of SAMSCA 30 MG TABLET 10S, a pharmaceutical product. The contract has an ultimate completion date of December 30, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $10,269.78 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. This contract is for the delivery of SAMSCA 15 MG TABLET 10S pharmaceutical products, with a performance period ending on March 27, 2024. Amerisourcebergen Drug Corp, a for-profit organization, has previously received numerous federal contract awards from DLA Troop Support Medical to supply pharmaceuticals,...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of SAMSCA 15 MG TABLET 10S. The contract is a Firm Fixed Price Delivery Order valued at $10,261.68, with a period of performance through March 24, 2023. The contract was not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 through...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The $20,539.62 contract is for the delivery of SAMSCA 15 MG TABLET 10S to a location in Conshohocken, Pennsylvania. The contract has a completion date of February 16, 2024 and was awarded on January 26, 2024. This delivery order is issued under a larger, single-award indefinite delivery...
- This federal contract award, valued at $10,623.60, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the provision of SAMSCA 15 MG TABLET 10S, a medical product, with a performance period ending on March 13, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of SAMSCA 15 MG TABLET 10S, a pharmaceutical product, with a ceiling value of $10,623.60 and a performance period extending through June 13, 2025. The contract is not designated as a set-aside and was competitively awarded. AmerisourceBergen Drug Corp holds a...
- The Defense Logistics Agency awarded a $42,588.96 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 30 mg SAMSCA tablets. The prime contractor will deliver 10,000 tablets to a facility in Conshohocken, Pennsylvania by July 24, 2023. The Defense Logistics Agency manages the Department of Defense's global logistics network and supply chain, and this delivery order was awarded under an existing indefinite-delivery/indefinite-quantity contract vehicle. No subcontractors or...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $12,584.40 by the Defense Logistics Agency (DLA) Medical Supply Chain on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed price, non-set-aside contract represents a child order under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. The delivery order will be fulfilled at...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency valued at $18,339.50 on July 18, 2025, with an ultimate completion date of July 21, 2025. The award is for Gemtesa 75 mg tablets in a quantity of 90 units under a firm fixed price contract type with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJC61Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 28, 2025, for the supply of Samsca 15 mg tablets (10-count packages) valued at $7,082.40 with a firm fixed price structure. The contract, which is not set-aside and was competitively awarded, requires completion by August 18, 2025, with performance to be executed from the company's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and runs through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. The company's comprehensive contract portfolio demonstrates its capability to supply brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to federal customers including the Defense Health Agency and U.S. Coast Guard. The DLA is currently planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, further solidifying AmerisourceBergen Drug Corp's role as a key supplier within the federal healthcare procurement ecosystem.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1k | 7/28/25 |